

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

EPAS ID: PAT6828099

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
SAI LIFE SCIENCES LIMITED	11/27/2019
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	CV6 THERAPEUTICS (NI) LIMITED
<b>Street Address:</b>	MURRAY HOUSE, 4 MURRAY STREET
<b>City:</b>	BELFAST
<b>State/Country:</b>	UNITED KINGDOM
<b>Postal Code:</b>	BT1 6DN
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
Application Number:	17320650
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Email:</b>	ipdocketing@foley.com, jyo@foley.com
<b>Correspondent Name:</b>	FOLEY & LARDNER LLP
<b>Address Line 1:</b>	3000 K STREET N.W.
<b>Address Line 2:</b>	SUITE 600
<b>Address Line 4:</b>	WASHINGTON, D.C. 20007-5109
<b>ATTORNEY DOCKET NUMBER:</b>	109290-0227
<b>NAME OF SUBMITTER:</b>	JESSICA YO
<b>SIGNATURE:</b>	/Jessica Yo/
<b>DATE SIGNED:</b>	07/22/2021
<b>Total Attachments: 3</b>	
source=109290-0227 Parent Executed Assignment - Sai to CV6#page1.tif	
source=109290-0227 Parent Executed Assignment - Sai to CV6#page2.tif	
source=109290-0227 Parent Executed Assignment - Sai to CV6#page3.tif	

## PATENT ASSIGNMENT

WHEREAS Sai Life Sciences Limited, having an address at L4, SLN Terminus, Gachibowli, Hyderabad 500032, Telangana, India (hereinafter "Assignor") is the owner of the patent applications and patents, and the inventions described therein (hereinafter referred to as "the Patents") listed on the attached EXHIBIT A.

WHEREAS CV6 Therapeutics (NI) Limited, having an address at Murray House, 4 Murray Street, Belfast, BT1 6DN, United Kingdom 02116 (hereinafter referred to as "Assignee") is desirous of acquiring the entire right, title and interest in and to the Patents;

WHEREAS, Assignor desires to transfer to Assignee the entire right, title and interest in and to the Patents.

NOW THEREFORE, for good and valuable consideration of at least \$1.00 (U.S.), the receipt and sufficiency of which are hereby acknowledged, Assignor by these presents does sell, assign, transfer and convey unto Assignee, its successors, assigns and legal representatives, its entire, right, title and interest in and throughout the United States (including its territories and dependencies) and all countries foreign thereto:

(a) in and to the inventions disclosed in the Patents;

(b) in and to the Patents and any and all related United States and foreign patent applications disclosing said inventions, including provisionals, nonprovisionals, divisions, continuations, continuations-in-part, and continued prosecution applications and any other related United States and foreign patent applications thereof, along with all rights of priority created by said patent applications under the Paris Convention, and any other relevant international agreements;

(c) in and to all United States and foreign patents which may be granted on any and all of said applications, including extensions, reissues and reexamination certificates thereof; and

(d) in and to all rights to sue for and damages resulting from past, present and future infringement of all United States and foreign patents granted or to be granted on said applications and inventions disclosed therein, and related patents and patent applications including extensions, reissues, and reexamination certificates thereof;

said inventions, patents and patent applications, and rights to damages to be held and enjoyed by the above-named Assignee, for Assignee's own use and benefit, and for Assignee's legal representatives and assigns to the full end of the term or terms for which said patents may be granted, as fully and entirely as the same would have been held by the undersigned Assignor had this assignment and sale not been made.

Upon request of Assignee, and without further remuneration, Assignor will execute any and all papers desired by Assignee for the filing and granting of patent applications and the perfecting of title thereto in Assignee.

Sai Life Sciences Limited (Assignor)

Date: NOVEMBER 07, 2019

By: \_\_\_\_\_

Name: \_\_\_\_\_

Title: \_\_\_\_\_

CV6 Therapeutics (NI) Limited (Assignee)

Date: NOVEMBER 12, 2019

By: \_\_\_\_\_

Name: \_\_\_\_\_

Title: \_\_\_\_\_

**EXHIBIT A**

<b>COUNTRY</b>	<b>APPLN. NO.</b>	<b>TITLE</b>
India	740/KOL/2015	HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS
P.C.T.	PCT/IB2016/054091	HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS
Australia	2016290987	HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS
Brazil	112018000248-8	HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS
Canada	2991468	HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS
China	201680051434.1	HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS
EAPO	201890247	HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS
Europe	16753974.1	HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS
Hong Kong	18108111.7	HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS
Israel	256221	HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS
India	201827004586	HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS
Japan	2018-520047	HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS
New Zealand	739583	HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS
U.S.	15/741202	HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS
U.S.	15/914958	HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS
South Africa	2018/00794	HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS